[{"orgOrder":0,"company":"George Medicines","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Metformin","moa":"||NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase II","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ CUREator","highestDevelopmentStatusID":"8","companyTruncated":"George Medicines \/ CUREator"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"HighTide Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Endocrinology","graph2":"Phase II","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Quotient Sciences \/ HighTide Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Quotient Sciences \/ HighTide Therapeutics"}]

Find Endocrinology Drugs in Phase II Clinical Development in UNITED KINGDOM

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Berberine Ursodeoxycholate

                          Therapeutic Area : Endocrinology

                          Study Phase : Phase II

                          Sponsor : HighTide Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Details : HTD1801 (berberine ursodeoxycholate), is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).

                          Product Name : HTD1801

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 15, 2022

                          Lead Product(s) : Berberine Ursodeoxycholate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : HighTide Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Quotient

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and saf...

                          Product Name : GMRx4

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 20, 2022

                          Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : CUREator

                          Deal Size : $1.0 million

                          Deal Type : Financing

                          blank